Orchestra BioMed Holdings (OBIO) Earnings Analysis

Orchestra BioMed Holdings (OBIO) next reports earnings on 2026-08-11, consensus EPS -0.35 USD. Last quarter (2026-03-12) it beat with EPS 0.26 USD vs -0.38 USD est (+168.4%). It has beaten estimates in 2/4 recent quarters (50%). Trailing P/E -2.56.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does OBIO next report earnings?

Next earnings date2026-08-11
Consensus EPS estimate-0.35 USD
Revenue estimate0.00B

OBIO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-120.26 USD-0.38 USD+168.4%Beat
2025-11-10-0.4 USD-0.38 USD-5.3%Miss
2025-04-02-0.43 USD-0.43 USD0%Beat
2024-08-12-0.45 USD-0.41 USD-9.8%Miss

Beat rate: 2/4 (50%) over reported quarters with consensus data.

OBIO valuation and analyst view

Trailing P/E-2.56
Trailing EPS-1.42311 USD
Price / book2.73
Dividend yield0.00%
Market cap0.22B
Analyst consensusBuy (4 buy / 1 hold / 0 sell)
Avg price target13 USD

Related research pages

Frequently asked questions

When is Orchestra BioMed Holdings (OBIO)'s next earnings date?

Orchestra BioMed Holdings is next scheduled to report on 2026-08-11, with a consensus EPS estimate of -0.35 USD and revenue estimate of 0.00B.

Did OBIO beat earnings last quarter?

In its 2026-03-12 report, OBIO posted EPS of 0.26 USD versus a -0.38 USD estimate — a beat of 168.4%.

What is OBIO's earnings track record?

Over the last 4 reported quarters with consensus data, OBIO beat estimates 2 times (50%).

What is OBIO's current P/E ratio and EPS?

OBIO trades at a trailing P/E of -2.56 on trailing EPS of -1.4231084875579003 USD.

What do analysts rate OBIO?

Analyst consensus is "Buy" across 5 ratings (0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 13 USD.